
HCA Healthcare (HCA) Stock Forecast & Price Target
HCA Healthcare (HCA) Analyst Ratings
Bulls say
HCA Healthcare's EBITDA in the fourth quarter of 2024 demonstrated resilience, growing over 6% when excluding the impact of state DPPs and accounting for hurricane effects, indicating robust operational performance. The company experienced significant growth in same-store inpatient surgeries, with a year-over-year increase of 180 basis points, reflecting strong demand and management's effective execution strategies. Furthermore, HCA's substantial market presence, characterized by an unmatched scale and infrastructure, positions it favorably for continued market share gains and enhances its outlook within the competitive healthcare landscape.
Bears say
HCA Healthcare's stock outlook is negatively impacted by uncertainties surrounding Medicaid direct payment programs and a projected decline in equivalent admissions for 2025. The firm anticipates headwinds from various factors including non-recurrence of leap year effects and regulatory challenges, resulting in a lowered adjusted EBITDA estimate to $14.58 billion. Additionally, the market faces potential multiple compression, which undermines the positive re-rating the company has experienced in recent years, highlighting a turbulent financial landscape ahead.
This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.
HCA Healthcare (HCA) Analyst Forecast & Price Prediction
Start investing in HCA Healthcare (HCA)
Order type
Buy in
Order amount
Est. shares
0 shares